Well-funded AI startup cooking up 5 health & nutrition products

An Irish AI startup whose investors have already raised $65 million is pledging to deliver a breakthrough natural food additive by the end of this year and four more by 2021.

The company, called Nuritas, says the first of its offerings to hit the shelves will be an AI-discovered ingredient that helps relieve inflammation.

The company is aiming its products at the sports-nutrition market, Yahoo Finance UK is reporting.

“We believe not only that we have launched the only healthcare ingredient found through AI, but we will in fact launch the second, third, fourth and fifth within a 12- to 18-month period as well,” CEO Emmet Browne tells Yahoo reporter Edmund Heaphy. “In effect, what we do is use artificial intelligence to unlock nature’s secrets. That’s the depth of it.”

Nuritas is a founding member of the Alliance for Artificial Intelligence in Healthcare and counts among its investors U2 bandmates Bono and the Edge, Salesforce founder Marc Benioff and the Iranian-American entrepreneur and angel investor Ali Partovi.

The company’s methodology involves identifying a range of potentially healthful natural substances in stages, then using AI to home in on the most promising ones, according to Yahoo Finance.

Browne says around 60% of these turn out to have sufficiently impressive “bioactive activity” to make them worth pursuing as potential products.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.